MC0518
Sponsors
Medac Gesellschaft fuer klinische Spezialprapaerate mbH, Azienda Socio Sanitaria Territoriale Degli Spedali Civili Di Brescia, medac GmbH
Conditions
Gvhd Resistant to ruxolitinib and steroidsSteroid refractory Acute Graft versus host DiseaseSteroid-refractory Acute Graft-versus-host Disease
Phase 2
A Randomised, Open label, Controlled, Multicentre, Phase 2 Trial of First line Treatment with Mesenchymal Stromal Cells MC0518 Versus Best Available Therapy in Paediatric Participants with Steroid refractory Acute Graft versus host Disease After Allogeneic Stem Cell Transplantation (BALDER Trial)
RecruitingCTIS2023-503952-28-00
Start: 2023-11-13Target: 54Updated: 2025-05-21
Trial of Efficacy and Safety of MC0518 Versus Best Available Therapy in Participants With Steroid-Refractory Acute Graft Versus Host Disease
Active, not recruitingNCT06075706
Start: 2023-11-13End: 2031-06-01Updated: 2026-04-14
Efficacy of cell therapy with allo-MSCs in patients with gvhd resistant to ruxolitinib second line therapy: a Phase IIB Clinical Trial - MSC-GRR2 Study
Not yet recruitingCTIS2025-523448-10-00
Target: 26Updated: 2026-04-28
Phase 3
Treatment Of Steroid-Refractory Acute Graft-versus-host Disease With Mesenchymal Stromal Cells Versus Best Available Therapy
RecruitingNCT04629833
Start: 2021-08-16End: 2030-08-31Target: 210Updated: 2025-08-13
A Randomised, Open label, Multicentre, Phase 3 Trial of First line Treatment with Mesenchymal Stromal Cells MC0518 Versus Best Available Therapy in Adult and Adolescent Subjects with Steroid refractory Acute Graft versus host Disease After Allogeneic Haematopoietic Stem Cell Transplantation (IDUNN Trial)
RecruitingCTIS2023-505737-26-00
Start: 2020-07-22Target: 210Updated: 2025-12-18